Contract analysis
Clause-by-clause risk read on any document of the firm. Pick a contract, or open any document from a matter.
Contract analysis / cost-sharing-ratio-analysis.xlsx
cost-sharing-ratio-analysis.xlsx
High · 1
Medium · 0
Standard · 0
[sheet: Cover & Summary]
High
⚑ Penalty / liquidated damages
[sheet: Cover & Summary] Field | Detail Document Title | Cost-Sharing Ratio Analysis — Reasonably Anticipated Benefits (TY 2017–2020) Prepared By | Garrett Simmons, Calderwood & Harkness LLP / Dr. Helena Vasquez & Dr. Rohan Chakrabarti, Whitmore Valuation Group LLC Matter Number | 1018-00009 Kovel Reference | 1018-00009-KV Client | Penterra Pharmaceuticals Corp. (EIN: 22-3741856) Subject Entity | Penterra Biopharma I